Zai Lab wins China approval for Tivdak in cervical cancer
Bottom line
Zai Lab said China’s National Medical Products Administration has approved Tivdak (tisotumab vedotin) for adults with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy, giving the company a new commercial oncology launch in Greater China and extending Tivdak’s reach beyond prior approvals in the U.S., EU, U.K., Japan, and Hong Kong. The approval is based in part on the global phase 3 innovaTV 301 study, which supported full U.S. approval in April 2024 after an earlier accelerated approval in 2021. (businesswire.com)
Why it matters: For veterinary professionals tracking oncology drug development, this is another sign that antibody-drug conjugates are continuing to gain regulatory momentum across markets, with tissue factor-targeting now backed by phase 3 survival data in a hard-to-treat solid tumor. In innovaTV 301, tisotumab vedotin improved overall survival versus investigator’s choice chemotherapy in previously treated recurrent cervical cancer, with median overall survival of 11.5 months versus 9.5 months. That kind of global validation can shape how clinicians, researchers, and industry teams think about ADC platform durability, cross-border commercialization, and future comparative oncology interest. (nejm.org)
What to watch: Watch for Zai Lab’s China launch plans, reimbursement and access decisions, and whether additional regional data presentations help define uptake in the Chinese gynecologic oncology market. (businesswire.com)
Key facts
- Company
- Zai Lab
- Regulator
- China’s National Medical Products Administration
- Drug
- Tivdak (tisotumab vedotin)
- Indication
- Adults with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy
- Region
- Greater China
- Prior approvals
- U.S., EU, U.K., Japan, and Hong Kong
- Supporting study
- Global phase 3 innovaTV 301
- Overall survival
- 11.5 months versus 9.5 months with chemotherapy
Zai Lab has won approval from China’s National Medical Products Administration for Tivdak (tisotumab vedotin) in adults with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy, marking a significant expansion for the antibody-drug conjugate in Greater China. The June 2026 announcement positions Tivdak as part of Zai Lab’s growing women’s oncology portfolio and follows earlier approvals in the U.S., EU, U.K., Japan, and Hong Kong. (businesswire.com)
The approval builds on several years of regulatory and clinical momentum. Tivdak first secured accelerated approval in the U.S. in September 2021 for previously treated recurrent or metastatic cervical cancer, then converted to full approval in April 2024 after confirmatory phase 3 data from innovaTV 301 showed a survival benefit over single-agent chemotherapy. Zai Lab had previously reported positive topline results in the China subpopulation of the global phase 3 trial and said in early 2025 that it intended to file in China. (businesswire.com)
Mechanistically, Tivdak is an antibody-drug conjugate directed at tissue factor, using Pfizer ADC technology to deliver the microtubule-disrupting payload MMAE. In the global innovaTV 301 study, patients with recurrent cervical cancer after first-line systemic therapy were randomized against investigator’s choice chemotherapy. The trial showed significantly longer overall survival with tisotumab vedotin, and outside coverage of the data reported median overall survival of 11.5 months with Tivdak versus 9.5 months with chemotherapy. (businesswire.com)
Zai Lab said it plans to leverage its existing commercial footprint in gynecologic oncology, including synergies with its Zejula team, as it brings Tivdak into the China market. That matters because recurrent or metastatic cervical cancer remains a setting with limited options after progression on chemotherapy, and regional commercialization strength often determines how quickly an approval translates into real-world use. The company had already gained approval for Tivdak in Hong Kong in September 2025, suggesting this China decision is part of a broader staged rollout across Greater China. (businesswire.com)
Public expert commentary tied specifically to the China approval was limited at the time of reporting, but industry messaging around the earlier full U.S. approval framed the drug as opening a new treatment path for a population with few established options. Independent medical coverage of innovaTV 301 has also emphasized that the study offered a direct head-to-head comparison against commonly used chemotherapy agents, strengthening the evidence package behind broader regulatory uptake. (pfizer.com)
Why it matters: For veterinary professionals, this is less about immediate clinical crossover and more about where oncology drug development is heading. ADCs continue to move from niche innovation to mainstream regulatory strategy, and Tivdak’s China approval underscores how platform-based cancer therapeutics are now being validated across multiple major markets. For animal health teams watching translational oncology, that can inform expectations around target selection, licensing strategy, and how human oncology success may eventually influence comparative cancer research and investor appetite. (businesswire.com)
There’s also a commercial lesson here. Zai Lab is not just importing a product, it’s using local regulatory execution plus an established oncology field presence to compete in a difficult but important cancer segment. That model, pairing global assets with regional commercialization infrastructure, is increasingly relevant across biopharma and may be useful for veterinary industry readers following how specialty therapeutics expand internationally. (businesswire.com)
What to watch: Next, the key questions are how fast Zai Lab can launch in mainland China, whether provincial reimbursement or hospital access supports uptake, and whether further China-specific analyses from innovaTV 301 shape prescribing confidence in routine practice. (businesswire.com)